MedChunk
Medically reviewed

FDA-Approved Alopecia Areata Treatments: Options That Work

Learn about FDA-approved alopecia areata treatments, including Olumiant, Litfulo, and Leqselvi. Compare hair regrowth results, age limits, risks, and treatment options.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 14 min read

Three medicines are FDA-approved to treat severe alopecia areata: Olumiant (baricitinib), Litfulo (ritlecitinib), and Leqselvi (deuruxolitinib). All three can help some people regrow hair by reducing the immune system's attack on hair follicles. They are prescription medicines taken by mouth, but they do not work for everyone and require medical monitoring.

Which Alopecia Areata Treatments Are FDA-Approved?

Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles. This can cause patches of hair loss or, in more extensive cases, loss of most or all scalp hair. The condition may also affect eyebrows, eyelashes, and other body hair.

The three FDA-approved treatments belong to a group of medicines called Janus kinase (JAK) inhibitors. These drugs reduce certain immune signals involved in the attack on hair follicles, allowing hair growth to resume in some patients.

According to the National Alopecia Areata Foundation, the FDA-approved JAK inhibitors are specifically intended for severe alopecia areata. Their approvals began in 2022 and expanded to include additional medicines and eligible age groups.

FDA-Approved Medicine Brand Name Eligible Age How It Is Taken
Baricitinib Olumiant 12 years and older Once-daily tablet
Ritlecitinib Litfulo 12 years and older Once-daily capsule
Deuruxolitinib Leqselvi Adults 18 years and older Twice-daily tablet

These age limits reflect U.S. approvals as of November 2026. Although all three medicines treat the same condition, they differ in their approved populations, dosing schedules, precautions, and clinical trial results.

Olumiant (Baricitinib): The First FDA-Approved Oral Treatment

Olumiant was the first oral JAK inhibitor approved by the FDA specifically for severe alopecia areata, receiving its initial alopecia areata approval in June 2022. Its approval was later expanded to include adolescents aged 12 years and older.

Baricitinib blocks JAK1 and JAK2 signaling pathways, which are involved in immune activity. Reducing these signals can help limit the immune attack on hair follicles.

How Well Does Olumiant Work?

Clinical trials have shown that baricitinib can produce substantial scalp hair regrowth in some adults with severe alopecia areata.

In major clinical trials, approximately 32% to 35% of adults taking the 4 mg daily dose achieved at least 80% scalp hair coverage after 36 weeks. Some patients also experienced eyebrow and eyelash regrowth.

These results are encouraging, but they do not mean everyone will achieve the same level of regrowth. Some patients respond more slowly, while others have limited improvement.

What Should Patients Know Before Taking Olumiant?

Olumiant is taken once daily. The prescribed dose depends on factors such as age, treatment response, kidney function, and other medical considerations.

Potential adverse effects include infections, acne, changes in cholesterol levels, and certain blood test abnormalities. Serious safety risks are also associated with this medicine, making screening and regular follow-up important.

Litfulo (Ritlecitinib): An Option for Adults and Teenagers

Litfulo received FDA approval in June 2023 for severe alopecia areata in adults and adolescents aged 12 years and older. It provides an approved treatment option for teenagers experiencing extensive hair loss.

Ritlecitinib blocks JAK3 and certain TEC family kinases involved in immune signaling. This action can reduce the immune activity affecting hair follicles.

How Effective Is Litfulo for Hair Regrowth?

The American Academy of Dermatology reports that, after approximately six months of treatment, 23% of patients taking ritlecitinib achieved at least 80% scalp hair coverage. Approximately 13.4% achieved at least 90% scalp coverage.

This means that some patients experience substantial regrowth within six months, although others may need a longer treatment period or may not respond sufficiently.

What Makes Litfulo Different?

Litfulo is taken as a once-daily capsule. Its approval for patients aged 12 years and older makes it relevant for adolescents as well as adults.

Possible side effects include headache, diarrhea, acne, and infections. Like other approved oral JAK inhibitors, it carries important warnings about serious infections and other potentially serious complications.

A dermatologist can help families understand whether the possible benefits justify the risks for an adolescent with severe alopecia areata.

Leqselvi (Deuruxolitinib): Another FDA-Approved Treatment for Adults

Leqselvi received FDA approval on July 25, 2024, for adults with severe alopecia areata. It is a JAK1 and JAK2 inhibitor taken twice daily.

By reducing immune signaling associated with alopecia areata, deuruxolitinib may allow hair follicles to resume producing hair.

What Did Clinical Trials Show?

According to the U.S. Food and Drug Administration, Leqselvi was evaluated in two clinical trials involving 1,209 adults with severe alopecia areata. Participants had experienced at least 50% scalp hair loss for more than six months.

At 24 weeks, approximately 30% of patients receiving the approved dose achieved at least 80% scalp hair coverage, while about 25% achieved at least 90% scalp coverage.

These findings demonstrate that the medicine can provide meaningful hair regrowth for a proportion of adults with extensive hair loss.

Important Precautions With Leqselvi

Leqselvi has some prescribing considerations that distinguish it from the other approved treatments. Certain inherited differences in how the body processes medicines and interactions with specific medications can make it unsuitable for some patients.

Its safety warnings include serious infections, blood clots, cardiovascular events, and certain cancers. Doctors also consider laboratory results and other health conditions before and during treatment.

Which FDA-Approved Alopecia Areata Medicine Works Best?

There is no single FDA-approved alopecia areata medicine that works best for every patient. All three have demonstrated clinically meaningful hair regrowth in controlled trials, but their results should not be treated as direct comparisons.

Different clinical trials may involve different patient groups, assessment periods, and treatment protocols. A higher percentage in one study does not necessarily prove that one medicine is more effective than another.

When selecting treatment, dermatologists consider several factors:

  • Extent of hair loss: How much scalp hair is affected and whether eyebrows or eyelashes are involved.
  • Age: Some medicines are approved for adolescents, while others are approved only for adults.
  • Medical history: Existing infections, cardiovascular conditions, previous blood clots, and other relevant conditions can affect treatment suitability.
  • Other medicines: Potential interactions may limit which drug can be used safely.
  • Treatment response: Previous hair regrowth, side effects, and changes during treatment help guide decisions.
  • Practical considerations: Dosing schedules, insurance coverage, cost, and access to monitoring may influence the choice.

A treatment plan should balance the likelihood of meaningful regrowth against the medicine's potential risks and the patient's goals.

How Long Does FDA-Approved Treatment Take to Work?

Hair regrowth with JAK inhibitors usually requires months of treatment rather than days or weeks. Some patients notice early changes, but a more complete assessment often takes longer.

Many clinical trials assess important hair regrowth outcomes at approximately 24 to 36 weeks. However, a patient's response may continue to develop beyond these time points.

The National Alopecia Areata Foundation describes U.S. expert consensus recommendations suggesting that adults with severe alopecia areata generally receive an adequate treatment trial of approximately 6 to 12 months before the response is fully assessed.

When treatment is helping, long-term therapy may be recommended to maintain hair regrowth. If the response is inadequate, a dermatologist may consider a different treatment after reviewing safety, adherence, and clinical progress.

Stopping an effective JAK inhibitor can be followed by renewed hair loss. These medicines control immune activity rather than permanently curing alopecia areata.

What Are the Safety Risks of FDA-Approved JAK Inhibitors?

All three FDA-approved oral JAK inhibitors carry boxed warnings, the FDA's most prominent prescription drug safety warnings.

These warnings address serious infections, malignancies, major adverse cardiovascular events, blood clots, and mortality. Some boxed warnings reflect findings with other JAK inhibitors in populations treated for different autoimmune diseases, so the exact level of risk for an individual alopecia areata patient is not always known.

More commonly reported adverse effects vary by medicine and may include acne, headache, digestive symptoms, infections, or changes in laboratory test results.

What Screening Is Needed Before Starting Treatment?

Before prescribing a JAK inhibitor, a healthcare professional may review medical history, current medications, vaccination status, and relevant laboratory tests.

Depending on the medicine, testing and monitoring may include:

  • Screening for tuberculosis and certain viral infections.
  • Complete blood counts to evaluate blood cells.
  • Liver function and other relevant laboratory tests.
  • Cholesterol monitoring when indicated.
  • Assessment of cardiovascular and blood clot risk factors.
  • Review of vaccination needs before treatment.

Pregnancy, plans for pregnancy, breastfeeding, and certain existing medical conditions also require specific discussion before treatment. Safety recommendations differ between medicines.

Patients should promptly report possible serious infections, unusual swelling or pain in a leg, chest pain, or breathing difficulties. Sudden chest pain, severe shortness of breath, or signs of a stroke require emergency medical attention.

Are Steroid Injections and Minoxidil FDA-Approved for Alopecia Areata?

Corticosteroid injections, topical corticosteroids, and minoxidil are used in alopecia areata care, but they do not have the same FDA-approved indication for alopecia areata as Olumiant, Litfulo, and Leqselvi.

A medicine can be FDA-approved for one condition and still be prescribed off-label for another. Off-label treatment means a clinician uses an approved medication for a purpose not specifically listed in its FDA-approved labeling.

The American Academy of Dermatology describes several treatment options for alopecia areata, including corticosteroid injections for limited patches of hair loss, topical therapies, and systemic medicines for more extensive disease.

Corticosteroid Injections

Dermatologists commonly use corticosteroid injections for localized alopecia areata. The medicine is injected into affected scalp areas to reduce inflammation and may encourage regrowth.

This approach can be useful when hair loss is limited to a few patches. However, repeated injections may be less practical for people with widespread scalp involvement.

Topical Corticosteroids

Prescription corticosteroid lotions, creams, foams, or solutions may be used in selected patients. Their effectiveness depends on the individual situation, and they do not consistently produce the same results as systemic treatment for extensive disease.

Minoxidil

Minoxidil is commonly associated with treatment for pattern hair loss. Dermatologists may also use it as an additional therapy for alopecia areata, but it does not directly address the underlying autoimmune attack in the same way as JAK inhibitors.

These approaches remain relevant, particularly for patients who do not need, cannot take, or prefer not to use an oral JAK inhibitor.

Can FDA-Approved Treatments Restore Eyebrows and Eyelashes?

Some patients taking JAK inhibitors experience regrowth beyond the scalp, including eyebrows and eyelashes.

Clinical studies of approved JAK inhibitors have reported improvements in eyebrow and eyelash hair in certain patients. However, regrowth in these areas is not guaranteed, and scalp hair response does not always predict eyebrow or eyelash recovery.

A dermatologist may evaluate these areas separately when assessing treatment progress. Eyelash loss can also create practical concerns related to eye comfort and protection, making appropriate eye care important.

Who Should Consider an FDA-Approved Alopecia Areata Treatment?

FDA-approved oral JAK inhibitors are primarily intended for patients with severe alopecia areata. They may be considered when extensive hair loss creates substantial physical, emotional, or practical difficulties.

A dermatologist evaluates the pattern and extent of hair loss, medical history, examination findings, and sometimes additional tests before recommending systemic therapy.

For individuals with a small number of hairless patches, local treatment or observation may be more appropriate. Alopecia areata can sometimes improve spontaneously, although future hair loss remains possible.

For more extensive or persistent disease, an approved oral treatment may offer a meaningful chance of regrowth. The decision involves discussing expected benefits, safety monitoring, treatment duration, and personal preferences.

What Happens if the First FDA-Approved Treatment Does Not Work?

An inadequate response to one JAK inhibitor does not necessarily mean every treatment option has been exhausted.

Dermatologists may reassess the amount of time spent on treatment, the amount of hair regrowth achieved, side effects, adherence, and other medical considerations.

Depending on the situation, they may recommend continuing treatment longer, changing to another approved JAK inhibitor, or considering additional therapies.

These changes should be made with medical supervision. Combining multiple powerful immune-suppressing medicines can increase safety concerns, and certain combinations are specifically discouraged in prescribing information.

Can Alopecia Areata Be Permanently Cured With These Medicines?

FDA-approved JAK inhibitors can help restore hair in some patients, but they are not considered permanent cures for alopecia areata.

The condition can remain active even when visible hair has regrown. Some people maintain a good response during ongoing treatment, while others experience renewed hair loss after treatment is stopped.

Successful care therefore involves more than achieving initial regrowth. Dermatologists also consider whether improvement can be maintained safely and whether continued treatment matches the patient's needs.

For patients with severe alopecia areata, the availability of three FDA-approved medicines represents a meaningful advance. These treatments provide evidence-based options that were not previously available, while making individualized decisions about effectiveness and long-term safety essential.

Frequently Asked Questions

Common questions about FDA-approved medicines, hair regrowth, and treatment decisions for alopecia areata.

What are the three FDA-approved medicines for alopecia areata?

The three FDA-approved oral medicines for severe alopecia areata are Olumiant (baricitinib), Litfulo (ritlecitinib), and Leqselvi (deuruxolitinib). All three belong to the JAK inhibitor drug class and can help some patients regrow hair by reducing immune activity affecting hair follicles.

Can a 12-year-old receive FDA-approved treatment for alopecia areata?

Yes. Olumiant and Litfulo are FDA-approved for severe alopecia areata in patients aged 12 years and older. Leqselvi is approved only for adults aged 18 years and older. Treatment for adolescents requires careful evaluation and monitoring by an appropriate healthcare professional.

How much hair can regrow with FDA-approved alopecia areata medicine?

Some patients regain at least 80% scalp hair coverage during treatment, while others experience partial regrowth or little improvement. Clinical trial results vary by medicine and follow-up period. A dermatologist can help explain the expected benefits and assess progress over several months.

Will hair fall out again after stopping Olumiant, Litfulo, or Leqselvi?

Hair loss can return after stopping an effective JAK inhibitor because alopecia areata is a long-term autoimmune condition. Some patients may need continued treatment to maintain regrowth. Decisions about stopping, restarting, or changing medication should be made with a dermatologist.

Are FDA-approved alopecia areata pills safer than steroid injections?

Neither treatment is automatically safer for every patient. Steroid injections primarily treat selected areas of hair loss, while oral JAK inhibitors affect immune signaling throughout the body and carry important systemic safety warnings. The appropriate option depends on disease extent, medical history, potential side effects, and treatment goals.

Citations

  1. National Alopecia Areata Foundation — FDA-Approved JAK Inhibitors
  2. American Academy of Dermatology — JAK Inhibitors: What Your Dermatologist Wants You to Know
  3. U.S. Food and Drug Administration — Drug Trials Snapshots: Leqselvi
  4. National Alopecia Areata Foundation — New U.S. Treatment Recommendations for Severe Alopecia Areata in Adults
  5. American Academy of Dermatology — Hair Loss Types: Alopecia Areata Diagnosis and Treatment
Share this article